Avadel Pharmaceuticals plc (AVDL )

Currency in USD Disclaimer
$22.95 -$0.61 (-2.59%)
Open 11/17/2025
$22.86
$23.36
$6.38
$23.57

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

  • Symbol AVDL
  • Company Avadel Pharmaceuticals plc
  • Price $22.95
  • Changes Percentage -2.59
  • Change -0.61
  • Day Low $22.86
  • Day High $23.36
  • Year High $23.57
  • Year Low $6.38
  • Market Cap $2,220,697,541
  • Price Avg 50 EMA (D) $16.65
  • Price Avg 200 EMA (D) $11.41
  • Exchange NASDAQ
  • Volume 2,965,964
  • Average Volume 2,662,058
  • Open $23.25
  • Previous Close $23.56
  • EPS -0.02
  • PE -1148.25
  • Earnings Announcement 2025-11-04 21:00:00
  • Shares Outstanding $96,699,218

Company brief: AVADEL PHARMACEUTICALS PLC (AVDL )

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

AVDL Corporation News

Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”

Avadel Board of Directors Declares Lundbeck Proposal a “Company Superior Proposal”

November 17, 2025 at 10:45 am ET

globenewswire.com -- THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014...

Income Statement